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The State of SLIT
As was noted in last month’s editorial, signiﬁcant progress has been made in the past yearin many aspects of Allergy and Immunology worldwide, especially in areas that are
spearheaded by WAO.
One of the critical aspects of our discipline is the use of allergen speciﬁc immuno-
therapy as treatment for allergic diseases. Originally, the empiric institution of this therapy
was found to have profound inﬂuences on diseases such as allergic catarrh or hay fever. The
current state of the art has been reviewed in many venues, and signiﬁcant information over
the past 20 years has accumulated that a particular route of administering immunotherapy,
namely sublingual immunotherapy (SLIT), has a particularly strong proﬁle in terms of
safety without sacriﬁcing the usual efﬁcacy associated with standard injection subcuta-
neous immunotherapy (SCIT). Potential mechanisms to underline this approach to speciﬁc
immunotherapy include the route of mucosal administration as being a particularly effective
form of inducing immune tolerance without some of the potential risks of parenteral
administration. The allergy diagnosis, the indication, initiation, and follow-up observation
of SLIT is the absolute domain of an experienced allergist.
The WAO has taken a signiﬁcant interest in potential mechanisms and efﬁcacy sur-
rounding SLIT immunotherapy. A number of important initiatives have been undertaken by
WAO to examine the proper mode of study for efﬁcacy and safety within the burgeoning
number of worldwide studies concerning SLIT. The dosage, clinical efﬁcacy, safety and
practical implications of this form of therapy are profound since the eventual administra-
tion of SLIT has signiﬁcant advantages over standard SCIT, and the potential use of this
approach worldwide becomes an issue of great interest for pharmacoeconomic and prac-
tical reasons.
Over the past year, signiﬁcant evaluation and speculation concerning this form of
therapy has appeared in many venues and journals, including our own journal where SLIT
was reviewed and pollen speciﬁc SLIT was evaluated in an observational study of the
oral allergy syndrome. Based on the initiatives and interest of the WAO, it is anticipated that
a number of position statements and summaries concerning the current state of the art of
SLIT and standards utilized for evaluation of SLIT trials that are underway will be forth-
coming this year.
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The development of proper dosages and speciﬁc indications for respiratory and other allergic diseases treatment by SLIT
will be critical. Acceptance of this kind of therapy in areas where IT has not made signiﬁcant inroads and has not been approved,
beyond Europe, will also be of critical importance. The use of this therapy in North America, Latin America, the Middle East,
Africa and Asia, will be an interesting development, which will be followed closely for the next few years. It is anticipated that a
number of papers and ﬁndings concerning SLIT will be published in the next year within our WAO Journal, and we will keep
abreast of developments published in other areas of allergy and immunology on this important subject. We anticipate and welcome
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